Investment Analysts’ Weekly Ratings Changes for Stryker (SYK)

A number of firms have modified their ratings and price targets on shares of Stryker (NYSE: SYK) recently:

• 9/22/2026 – Stryker had its price target lowered by TD Cowen from $355.00 to $298.00. They now have a “hold” rating on the stock.
• 9/18/2026 – Stryker had its price target lowered by Canaccord Genuity Group Inc. from $400.00 to $385.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Stryker had its price target lowered by Citigroup Inc. from $399.00 to $360.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Stryker had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $317.00 price target on the stock.
• 9/9/2026 – Stryker had its price target lowered by Wells Fargo & Company from $418.00 to $348.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Stryker had its “buy” rating reaffirmed by Citigroup Inc..
• 8/13/2026 – Stryker was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 8/8/2026 – Stryker was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/3/2026 – Stryker had its “outperform” rating reaffirmed by Citigroup Inc..
• 8/3/2026 – Stryker had its price target lowered by Citizens Jmp from $440.00 to $400.00. They now have a “market outperform” rating on the stock.
• 7/31/2026 – Stryker had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 7/31/2026 – Stryker had its price target lowered by Royal Bank Of Canada from $435.00 to $420.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Stryker was given a new $370.00 price target by Raymond James Financial, Inc..
• 7/31/2026 – Stryker had its price target lowered by Piper Sandler from $420.00 to $390.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Stryker was given a new $375.00 price target by Wolfe Research.
• 7/31/2026 – Stryker had its price target lowered by JPMorgan Chase & Co. from $400.00 to $350.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Stryker had its price target raised by Truist Financial Corporation from $330.00 to $340.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Stryker had its price target lowered by BTIG Research from $371.00 to $358.00. They now have a “buy” rating on the stock.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda Stryker sold 300,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.